Vitrolife's Press Release of Annual Accounts 2003

Vitrolife's Press Release of Annual Accounts 2003 Increase in sales with profit and positive cash flow · Total net sales were SEK 96,3 million (103,3 - net sales of SEK 28,1 million is from assigned companies) · Core business net sales increased by 28 per cent, in spite of negative currency influence, and amounted to SEK 96,3 million (75,2) · Gross profit totalled SEK 61,6 million (49,4) and in per cent of turnover of 64 per cent (48) · The group´s net result totalled SEK 44,7 million whereof SEK 42,3 million is an item affecting comparability regarding mainly the sales of Alife (-116,5 whereof items affecting comparability -89,4) · Operating result for quarter four amounted to SEK 3,0 million (-110,2 whereof -87,6 is items affecting comparability) · Result per share SEK 2,4 (-6,3) · Vitrolife divested in August its subsidiary which developed products for aestctic facial surgery based on cross-linked Hyaluronic acid to Mentor Corp., USA for SEK 60 million free of debt plus royalty on future sales · Vitrolife received market clearance from FDA to marketing EmbryoGlue® For further information, please contact: CEO: Magnus Nilsson Tel: +46 31 721 80 00 Mobile +46 708 22 80 61 CFO and IR agent: Anders Sävfält Tel: +46 31 721 80 00 Mobile: +46 708 22 80 13 Vitrolife is a global biomedical corporation that works with products for cell and tissue technology. The Vitrolife group consists of the parent company, Vitrolife AB (Publ) and two wholly owned subsidiaries: Vitrolife Sweden AB (Gothenburg, Sweden), Vitrolife Inc. (Denver, Colorado). The group's operations focused on three geographic areas. · Europe/Middle East · The Americas · Rest of the World Vitrolife's business concept is to develop, produce and sell advanced products and systems for the preparation, cultivation, preservation and support of cells, tissues and organs. ------------------------------------------------------------ This information was brought to you by Waymaker The following files are available for download: The full year end report

About Us

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction. Vitrolife has about 370 employees and the company’s products are sold in about 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.


Documents & Links